Vimarsana
Biggest News Aggregation in the World

Page 23 - Linical Evolution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Linical Evolution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Linical Evolution Today - Breaking & Trending Today

Redx Pharma honoured with commemorative plaque for cancer discovery - Vimarsana News

Redx Pharma honoured with commemorative plaque for cancer discovery

Redx has been presented with a commemorative plaque at its HQ at Alderley Park, in recognition of its discovery of pirtobrutinib, the active pharmaceutical ingredient (API) in Eli Lilly's cancer treatment Jaypirca.

Gilead and Arcus expand to include inflamation research programs - Vimarsana News

Gilead and Arcus expand to include inflamation research programs

A previously announced research collaboration between Gilead Sciences and Arcus Biosciences that was focused on oncology has been expanded to include inflammatory diseases therapies.

Redx Pharma honoured with commemorative plaque for cancer discovery - Vimarsana News

Redx Pharma honoured with commemorative plaque for cancer discovery

Redx has been presented with a commemorative plaque at its HQ at Alderley Park, in recognition of its discovery of pirtobrutinib, the active pharmaceutical ingredient (API) in Eli Lilly's cancer treatment Jaypirca.

Xequel Bio selects Societal CDMO to support clinical development of iNexin - Vimarsana News

Xequel Bio selects Societal CDMO to support clinical development of iNexin

Xequel Bio has selected Societal CDMO to support the ongoing clinical development of a patented new chemical entity based on its aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.

Xequel Bio selects Societal CDMO to support clinical development of iNexin - Vimarsana News

Xequel Bio selects Societal CDMO to support clinical development of iNexin

Xequel Bio has selected Societal CDMO to support the ongoing clinical development of a patented new chemical entity based on its aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.